The Paris-based company, founded in 2018, offers accessible and effective diagnostic and prognostic tools for predicting coma emergence in patients with severe traumatic brain injuries, cardiac arrest, or hemorrhagic stroke. Their diagnostic device, designed for hospitals, analyzes MRI in SaaS mode and is built upon over 15 years of clinical development. Braintale's products are based on medical needs understanding, fulfilling healthcare professionals and patients’ expectations, and aim to enable physicians to diagnose the recovery from coma by deciphering white matter to provide better care.